Search results
Results from the WOW.Com Content Network
Prescient Therapeutics Ltd (Prescient) was created in 2014 by bringing together two small molecule drug assets from separate US private companies (Pathway Oncology for PTX-100 and AKTivate Therapeutics for PTX-200) into the existing ASX-listed shell company Virax Holdings Ltd (Virax).
In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. [6] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. [7]
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.
8. Nikola Corporation (NASDAQ: NKLA)NKLA ranks 8th in our list of the best hydrogen fuel cell stocks to buy now. Nikola is one of the world’s most famous electric car technology companies.
Cellectis became a publicly traded company in 2007, and raised €21.2 million in a stock offering on Euronext. In 2010, it acquired Cyto Pulse, which had developed a new electroporation technology, [ 3 ] and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company. [ 2 ]
A first generation CAR containing a CD4 extracellular domain and a CD3ζ intracellular domain was used in the first clinical trial of chimeric antigen receptor T cells by the biotechnology company Cell Genesys in the mid 1990s, allowing adoptively transferred T cells to target HIV infected cells, although it failed to show any clinical ...
In December 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017. [9]
Mustang Bio was founded in 2015 and in the same year became a partner company of Fortress Biotech. [5] [7] In April 2017, Manuel Litchman took over as CEO of Mustang Bio, and in October of the same year, the company signed a lease with the University of Massachusetts Medicine Science Park in Worcester, MA, for a manufacturing facility to support the clinical development and commercialization ...